Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2022-002006-24-NL
EUCTR2022-002006-24-NLActive, not recruitingPhase 1

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

ArriVent BioPharma, Inc.0 sites375 target enrollmentStarted: February 9, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
375
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Signed Informed Consent Form
  • •2. Age = 18 years at time of signing Informed Consent Form
  • •3. Ability to comply with the study protocol, in the investigator’s judgment
  • •4. Measurable disease per RECIST v1.1.
  • •Note: Measurable lesion can neither be subject to local therapy such as radiotherapy nor used for biopsy in the Screening Period; if there is only 1 measurable lesion, this lesion will be permitted to be biopsied. However, the baseline radiologic examination should be performed for this lesion at least 14 days after biopsy.
  • •5. Histologically or cytologically documented, locally advanced or metastatic non-squamous NSCLC not amenable to curative surgery or radiotherapy
  • •6. Documented validated results confirming the presence of an EGFR exon 20 insertion mutation (i.e., addition of 1 or more amino acids) in tumor tissue or blood from local or central testing via:
  • •A validated NGS assay or a validated PCR test with confirmation by Sanger sequencing performed at a CLIA or equivalently certified laboratory.
  • •- If local testing does not meet the above criteria, then a central test designated by the Sponsor or a commercially available NGS assay should be performed as specified in the laboratory manual.
  • •7. Consent to provide archival tumor tissue specimen (FFPE tissue block [preferred] or at least 15 unstained, serially cut sections on slides from FFPE tumor specimen). The specimens should be provided during screening or no later than within 30 days of Cycle 1, Day 1 and must be accompanied by a pathology report.
  • •It is preferred that the specimen is prepared from the most recently collected and available tumor tissue.
  • •8. No prior systemic anticancer therapy regimens received for locally advanced or metastatic NSCLC including prior treatment with any EGFR-targeting agents (e.g., previous EGFR-TKIs, monoclonal antibodies, or bispecific antibodies)
  • •9. Patients who have received prior neo-adjuvant and/or adjuvant chemotherapy, immunotherapy, or chemoradiotherapy for non-metastatic disease must have experienced a treatment-free interval of at least 12 months.
  • •10. ECOG performance status of 0 or 1
  • •11. Life expectancy of = 12 weeks
  • •12. Adequate hematologic and organ function within 14 days prior to initiation of study treatment, defined by the following:
  • •Absolute neutrophil count = 1500/µL
  • •Hemoglobin = 9 g/dL
  • •Platelet count = 100,000/µL
  • •Total bilirubin = 1.5 × ULN or = 3 × ULN in the presence of documented Gilbert’s Syndrome (unconjugated hyperbilirubinemia)
  • •AST, ALT, and AP = 2.5 × ULN, with the following exceptions:
  • •- Patients with documented liver metastases may have AST, ALT, and/or AP = 5.0 × ULN.
  • •- Patients with documented bone metastases may have AP = 5.0 × ULN.
  • •Creatinine clearance = 45 mL/min on the basis of the Cockcroft-Gault estimation:
  • •(140 – age) × (weight in kg) × (0.85 if female)
  • •72 × (serum creatinine in mg/dL)
  • •INR = 1.5 × ULN and aPTT = 1.5 × ULN
  • •13. For WOCBP: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs.
  • •14. For men who are not surgically sterile: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating sperm.
  • •15. Patients with CNS metastases are eligible, provided they meet all of the following criteria:
  • •Measurable disease outside the CNS
  • •No ongoing requirement for corticosteroids as therapy for CNS metastases, with

Exclusion Criteria

  • •1. Inability or unwillingness to swallow pills
  • •2. Inability to comply with study and follow-up procedures
  • •3. Malabsorption syndrome or other conditions that would interfere with enteral absorption
  • •4. Pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures biweekly or more frequently
  • •Indwelling pleural or abdominal catheters may be allowed, provided the patient has adequately recovered from the procedure, is hemodynamically stable, and has symptomatically improved.
  • •5. Severe acute or chronic infections.
  • •6. In the setting of a pandemic or epidemic, screening for active infections should be considered according to local or institutional guidelines or those of applicable professional societies (e.g., American Society of Clinical Oncology or European Society for Medical Oncology).
  • •7. Previous interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis, or having ILD
  • •8. History of or active clinically significant cardiovascular dysfunction, including the following:
  • •History of stroke or transient ischemic attack within 6 months prior to first dose of study drug
  • •History of myocardial infarction within 6 months prior to first dose of study drug
  • •NYHA Class III or IV cardiac disease or congestive heart failure requiring medication
  • •Uncontrolled arrhythmias, or history of or active ventricular arrhythmia requiring medication
  • •Coronary heart disease that is symptomatic or unstable angina
  • •9. Mean resting QTc > 470 msec, obtained from triplicate ECGs, using the screening clinic ECG machine–derived Fridericia’s formula (QTcF) value
  • •10. Clinically significant prolonged QT interval or other arrhythmia or clinical status considered by investigators that may increase the risk of prolonged QT interval (e.g., complete left bundle branch block, third-degree atrioventricular block, second degree heart block, PR interval > 250 msec, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives, serious hypokalemia, heart failure) or current use of the drugs that may lead to prolonged QT interval
  • •11. Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab
  • •12. Significant traumatic injury or major surgical procedure within 4 weeks prior to Day 1 of Cycle 1
  • •13. Patients with chronic diarrhea, short bowel syndrome or significant upper GI surgery including gastric resection, a history of inflammatory bowel disease (e.g., Crohn’s disease or ulcerative colitis), or any active bowel inflammation (including diverticulitis)
  • •14. Any other diseases, pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results, or renders the patients at high risk from treatment complications (e.g., uncontrolled hypertension, active bleeding)
  • •15. Radiation therapy (other than palliative radiation to bone metastases and radiation to CNS metastases as described above) as cancer therapy within 4 weeks prior to initiation of study treatment
  • •16. Palliative radiation to bone metastases within 2 weeks prior to initiation of study drug
  • •17. Any unresolved toxicities from prior therapy (e.g., adjuvant chemotherapy) > Grade 1 at initiation of study drug, with the exceptions of alopecia and prior platinum thera

Investigators

Similar Trials

Recruiting
Phase 1
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung CancerTreatment of Patients with Previously Untreated, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion MutationsMedDRA version: 20.0Level: LLTClassification code 10079440Term: Non-squamous non-small cell lung cancerSystem Organ Class: 100000004864
EUCTR2022-002006-24-ESArriVent BioPharma, Inc.375
Not yet recruiting
Phase 3
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion MutationsLung cancer
NL-OMON53471ArriVent BioPharma, Inc.2
Recruiting
Phase 1
A STUDY TO INVESTIGATE THE SAFETY AND EFFECTIVENESS OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY FOR PATIENTS WITH NON-SMALL CELL LUNG CANCERon-Small Cell Lung CancerMedDRA version: 20.0Level: LLTClassification code: 10079440Term: Non-squamous non-small cell lung cancer Class: 10029104
CTIS2022-502977-41-00Arrivent Biopharma Inc.387
Recruiting
Phase 3
Phase 3 Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer.ocally advanced or metastatic non-squamous non-small cell lung cancer
JPRN-jRCT2011230009Imanishi Naoki42
Active, not recruiting
Phase 1
A trial investigating the safety and efficacy of the drug combination Sofosbuvir/Velpatasvir/GS-9857 for 8 weeks against Sofosbuvir/Velpatasvir for 12 weeks for subjects with hepatitis C
EUCTR2015-003460-36-GBGilead Sciences, Inc.943